Capricor Therapeutics (CAPR) filed a registration statement Wednesday for the potential sale of up to $300 million of securities from time to time in one or more offerings.
The filing covers common and preferred stock, debt securities, warrants, and units. It also includes an at-the-market program of up to $150 million of common stock.
Net proceeds are expected to be used for general corporate purposes.